

BIG BOOST in COVID 19 FIGHT : Panacea Biotec to produce Sputnik V vaccine

Panacea Biotec is delighted to announce the obtaining of the manufacturing license to produce Sputnik V vaccine in India.- Dr. Rajesh Jain



India, Delhi, Jul 6, 2021 ([Issuewire.com](https://www.issuewire.com)) - Panacea Biotec announces receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh

Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, announces receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India.

The batches produced at Panacea Biotec's facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India.

Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021.

Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

Dr. Rajesh Jain, Managing Director, for Panacea Biotech, said:

“Panacea Biotech is delighted to announce the obtaining of the manufacturing license to produce Sputnik V vaccine in India. At this occasion, we thank the leadership of our Hon’ble Prime Minister Modi ji and Government of India for timely handholding and expediting clearances to enable ‘Make in India’ vaccines.”

Sputnik V has a number of key advantages:

☐ The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

☐ Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

☐ The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

☐ There are no strong allergies caused by Sputnik V.

☐ The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

☐ The price of Sputnik V is less than \$10 per shot, making it affordable around the world.

Media Contact

Leoarts Communication

raientertainment@yahoo.com

Source : PANACEA BIOTEC

[See on IssueWire](#)